National Comprehensive Cancer Network 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Cancer-Causing Mutation Discovered in 1982 Finally Target of Clinical Trials
A recent article in the journal Cancer Discovery describes clinical trials at the University of Colorado Cancer Center and elsewhere that match drugs to this long-overlooked oncogene, offering targeted treatment options for cancers that harbor these gene abnormalities.
University of Colorado Cancer Center is one of the 25 NCCN Member Institutions.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 30, 2014 Category: Cancer & Oncology Source Type: news
NCCN Launches 3D Virtual Simulator Learning Platform
The NCCN 3D Virtual Simulator Learning Platform allows users to walk through the continuum of care approach to colorectal cancer in a risk-free environment with increasingly complex clinical presentations.
FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) has launched a 3D Virtual Metastatic Colorectal Cancer (mCRC) Simulator Learning Platform as part of the NCCN Continuing Education Program. To develop the 3D Virtual mCRC Simulator Learning platform, NCCN collaborated... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 6, 2014 Category: Cancer & Oncology Source Type: news
“Your Odds of Surviving Cancer Depend Very Much on where You Live,” NPR.com
This story features a study published in Lancet that surveyed more than 27 million patients internationally and revealed a huge gulf in cancer survival worldwide.
This story includes commentary from a physician at Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance-one of the 25 NCCN Member Institutions.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 4, 2014 Category: Cancer & Oncology Source Type: news
“Breast Cancer Vaccine Shows Promise in Slowing Progress,” TIME.com
An initial safety trial of a breast cancer vaccine has proven safe, with preliminary results suggesting the vaccine will slow cancer progression.
The vaccine, which is being developed by researchers at Washington University School of Medicine in St. Louis, is meant for patients with breast cancers that express a protein found only in breast tissue called mammaglobin-A.
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is one of the 25 NCCN Member ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 1, 2014 Category: Cancer & Oncology Source Type: news
“U.S. Smoking Rate Dips Again,” The New York Times
The smoking rate in the United States declined to 17.8 percent in 2013, down slightly from 18.1 percent the previous year, the Centers for Disease Control and Prevention reported Wednesday. The report found a decline in the number of smokers in the United States - 42 million in 2013, down from 45 million in 2005 - despite an increase in population.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 26, 2014 Category: Cancer & Oncology Source Type: news
“Research on a Rare Cancer Exposes Possible Route to New Treatments,” Huntsman Cancer Institute at the University of Utah
Researchers from Huntsman Cancer Institute at the University of Utah-one of the 25 NCCN Member Institutions-discovered the unusual role of lactate in the metabolism of alveolar soft part sarcoma (ASPS), a rare, aggressive cancer that primarily affects adolescents and young adults. The study also confirmed that a fusion gene is the cancer-causing agent in this disease. The research results were published online in the journal Cancer Cell on November 26.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 26, 2014 Category: Cancer & Oncology Source Type: news
“Protein Predicts Response to New Immunotherapy Drug,” Yale Cancer Center/Smilow Cancer Hospital
The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.
The study, led by a Yale Cancer Center investigator, is described in the November 27 edition of the journal Nature.
Yale Cancer Center and Smilow Cancer Hospital is one of the 25 NCCN Member Institutions.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 26, 2014 Category: Cancer & Oncology Source Type: news
Changing the Course of Prostate Cancer Treatment: Life Expectancy Estimation, Active Surveillance, and Drug Development
NCCN has published the 20th annual edition of the NCCN Guidelines® for Prostate Cancer, one of the eight original NCCN Guidelines published in November 1996.
FORT WASHINGTON, PA-The National Comprehensive Cancer Network® (NCCN®) has published the 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer-one of the eight original NCCN Guidelines® published in November 1996.
'We have made an incredible amount of progress in the diagnosis... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 23, 2014 Category: Cancer & Oncology Source Type: news
Improved Outcomes in Non-Small Cell Lung Cancer Due to Advancements in Screening, Diagnosis, Radiology, and Systemic Therapies
NCCN has published the 20th annual edition of the NCCN Guidelines® for NSCLC, one of the eight original NCCN Guidelines published in November 1996.
FORT WASHINGTON, PA-The National Comprehensive Cancer Network® (NCCN®) has published the 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (NSCLC), one of the eight original NCCN Guidelines® published in November 1996.
'Since the first NCCN Guidelines for NSCLC were publis... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 21, 2014 Category: Cancer & Oncology Source Type: news
“Study Reveals How Some Breast Cancers Become Resistant to Targeted Drugs,” Memorial Sloan Kettering Cancer Center
A team of researchers from Memorial Sloan Kettering and elsewhere has gained new insights into how tumors develop resistance to targeted drugs. The findings suggest that adding additional drugs to the treatment regimen may provide a longer-lasting response and a greater benefit to patients.
Memorial Sloan Kettering Cancer Center is one of the 25 NCCN Member Institutions.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 20, 2014 Category: Cancer & Oncology Source Type: news
“Moffitt Cancer Center Researchers Use Evolutionary Principles to Model Cancer Mutations, Discover Potential Therapeutic Targets,” Moffitt Cancer Center
Moffitt Cancer Center researchers are taking a unique approach to understanding and investigating cancer by utilizing evolutionary principles and computational modeling to examine the role of specific genetic mutations in the Darwinian struggle among tumor and normal cells during cancer growth.
Moffitt Cancer Center is one of the 25 NCCN Member Institutions.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 19, 2014 Category: Cancer & Oncology Source Type: news
“Power behind ‘Master’ Gene for Cancer Discovered,” The University of Texas MD Anderson Cancer Center
A study at The University of Texas MD Anderson Cancer Center led by Mong-Hong Lee, Ph.D., a professor of molecular and cellular oncology, has demonstrated the significance of CSN6 in regulating Myc, which may very well open up a new pathway for treating and killing tumors. The study results are published in this month's issue of Nature Communications.
The University of Texas MD Anderson Cancer Center is one of the 25 NCCN Member Institutions.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 19, 2014 Category: Cancer & Oncology Source Type: news
“Study Shows Link Between Genes, Seaside VacationsandFuture Melanoma Risk,” University of Colorado Cancer Center
A longitudinal study established a link between different ultraviolet (UV) exposure measures in children, such as the number of waterside vacations or sunburns, and biomarkers of melanoma risk, such as the number of freckles or moles that develop during childhood, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
This story features commentary from an investigator at University of Colorado Cancer Center-... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 19, 2014 Category: Cancer & Oncology Source Type: news
“Potential Therapy Found for Incurable Pediatric Brain Tumor,” Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Northwestern Medicine scientists have discovered a new potential drug therapy for a rare, incurable pediatric brain tumor by targeting a genetic mutation found in children with the cancer.
By inhibiting the tumor-forming consequences of the mutation using an experimental drug called GSKJ4, they delayed tumor growth and prolonged survival in mice with pediatric brainstem glioma.
Robert H. Lurie Comprehensive Cancer Center at Northwestern University is one of the 25 NCCN Member Institutions.... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 17, 2014 Category: Cancer & Oncology Source Type: news
"Gene Sequencing Projects Link Two Mutations to Ewing Sarcoma Subtype with Poor Prognosis," St. Jude Children’s Research Center/The University of Tennessee Health Science Center
An international collaboration has identified frequent mutations in two genes that often occur together in Ewing sarcoma (EWS) and that define a subtype of the cancer associated with reduced survival. The research, conducted by the St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project and the Institut Curie-Inserm through the International Cancer Genome Consortium, appears in the current issue of the scientific journal Cancer Discovery.
St. Jude Children'... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 12, 2014 Category: Cancer & Oncology Source Type: news
